chr9-35074112-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_004629.2(FANCG):āc.1865T>Cā(p.Leu622Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,613,572 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ). Synonymous variant affecting the same amino acid position (i.e. L622L) has been classified as Likely benign.
Frequency
Consequence
NM_004629.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FANCG | NM_004629.2 | c.1865T>C | p.Leu622Pro | missense_variant | 14/14 | ENST00000378643.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FANCG | ENST00000378643.8 | c.1865T>C | p.Leu622Pro | missense_variant | 14/14 | 1 | NM_004629.2 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152214Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251466Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135914
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461358Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727042
GnomAD4 genome AF: 0.000105 AC: 16AN: 152214Hom.: 0 Cov.: 32 AF XY: 0.000134 AC XY: 10AN XY: 74356
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 14, 2020 | DNA sequence analysis of the FANCG gene demonstrated a sequence change, c.1865T>C, in exon 14 that results in an amino acid change, p.Leu622Pro. This sequence change does not appear to have been previously described in patients with FANCG-related disorders and has been described in the gnomAD database with a frequency of 0.03% in the African sub-population (dbSNP rs771669019). The p.Leu622Pro change affects a moderately conserved amino acid residue located in a domain of the FANCG protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Leu622Pro substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Leu622Pro change remains unknown at this time. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at